Lilly Asia Ventures was among the investors in a series B round for the renal disease treatment developer, which it incubated in 2018.
China-based renal disease therapy developer Alebund Pharmaceuticals has received $60m in a series B round that included Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly.
Life sciences venture capital firm Quan Capital led the round, which also featured healthcare-focused fund 3E Bioventures Capital, private equity firm Sherpa Healthcare Partners, VC firm Med-Fine Capital and an unnamed sovereign wealth fund.
Alebund is working on small molecule and biologics drugs to treat renal conditions including complications related to…
